ArriVent
is a Pennsylvania-based biotechnology company that researches and develops novel therapeutics for the treatment of cancer... Read moreArriVent
is a Pennsylvania-based biotechnology company that researches and develops novel therapeutics for the treatment of cancer... Read more
News
Mar 20, 2025
Benzinga
ArriVent: ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside
Mar 04, 2025
Owler
ArriVent Biopharma, Inc.: ArriVent's employee count changed from 40 in Dec 2023 to 52 in Dec 2024
Mar 03, 2025
Marketscreener
ArriVent: ArriVent BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024
Jan 23, 2025
Pharmabiz
ArriVent: ArriVent BioPharma inks exclusive license with Lepu Biopharma for MRG007, an ADC to treat gastrointestinal cancers
Jan 22, 2025
The Business Journals: Philadelphia
ArriVent: ArriVent bets big on experimental cancer drug with potential $1B licensing deal
Jan 22, 2025
MedCity News
ArriVent: Cancer Biotech ArriVent Lands an ADC for GI Malignancies and Makes Best-in-Class Claim
Nov 15, 2024
Seeking Alpha
ArriVent: ArriVent BioPharma GAAP EPS of -$0.61 beats by $0.11
Nov 14, 2024
Marketscreener
ArriVent: ArriVent BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
Sep 17, 2024
Seeking Alpha
ArriVent: ArriVent BioPharma: Bringing A Novel Cancer Drug From China
Sep 10, 2024
Nasdaq
ArriVent: ArriVent Announces Positive Phase 1b Data For Firmonertinib In NSCLC With EGFR PACC Mutations
ArriVent Competitors
1
2
3
4
5